Inventage Lab said on the 28th that it registered a domestic patent for technology to formulate Eli Lilly and Company's oral obesity and diabetes drug candidate Orforglipron into a long-acting injectable. A long-acting injectable is a technology that allows a single injection to maintain efficacy for more than a month.
The company said it is the first case to secure rights by implementing Orforglipron as a long-acting injectable. Orforglipron is a follow-up drug candidate from Eli Lilly and Company, which launched the obesity drug Mounjaro, and is being developed in a pill form that must be taken daily.
Inventage Lab applied its platform technology to convert it into an injection formulation administered once every 1 to 3 months and registered a patent in Korea. Inventage Lab has a platform technology that can convert glucagon-like peptide (GLP)-1 class small molecules and peptide drugs into injectable formulations. The company completed a Patent Cooperation Treaty (PCT) international application and plans to proceed, based on this, with entry procedures for individual countries in major global markets including the United States, Europe and Japan.
Through a patent registration based on semaglutide that is being researched and developed together with Yuhan, the company also succeeded in securing rights to specific pharmacokinetic control technology that maintains a steady blood concentration of the drug injected into the body over a long period.
The company said, "It will solve the inconvenience of having to take medicine every day and improve patients' medication adherence, while minimizing gastrointestinal side effects such as nausea, vomiting and diarrhea that occur early after taking oral medication."
Kim Ju-hee, CEO of Inventage Lab, said, "With our core registered patents already secured and this first registered patent for Orforglipron, we have shown that we possess the most advanced long-acting formulation derivation technology in the field of obesity treatments." Kim said, "Based on our technology, we will strengthen our capabilities in long-acting injectable formulations for obesity and metabolic disease treatments based on various peptides and small molecules."